These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine. Marjuki H; Topaz N; Joseph SJ; Gernert KM; Kersh EN; ; Wang X mBio; 2019 Sep; 10(5):. PubMed ID: 31506309 [TBL] [Abstract][Full Text] [Related]
5. An open-label randomised controlled trial evaluating the efficacy of a meningococcal serogroup B (4CMenB) vaccine on Neisseria gonorrhoeae infection in gay and bisexual men: the MenGO study protocol. Thng C; Semchenko EA; Hughes I; O'Sullivan M; Seib KL BMC Public Health; 2023 Mar; 23(1):607. PubMed ID: 36997957 [TBL] [Abstract][Full Text] [Related]
6. Prevention of Neisseria gonorrhoeae With Meningococcal B Vaccine: A Matched Cohort Study in Southern California. Bruxvoort KJ; Lewnard JA; Chen LH; Tseng HF; Chang J; Veltman J; Marrazzo J; Qian L Clin Infect Dis; 2023 Feb; 76(3):e1341-e1349. PubMed ID: 35642527 [TBL] [Abstract][Full Text] [Related]
8. Exploitation of Petousis-Harris H; Radcliff FJ Front Immunol; 2019; 10():683. PubMed ID: 31024540 [TBL] [Abstract][Full Text] [Related]
9. Potential impact of vaccination against Neisseria meningitidis on Neisseria gonorrhoeae in the United States: results from a decision-analysis model. Régnier SA; Huels J Hum Vaccin Immunother; 2014; 10(12):3737-45. PubMed ID: 25483706 [TBL] [Abstract][Full Text] [Related]
10. The Serogroup B Meningococcal Vaccine Bexsero Elicits Antibodies to Neisseria gonorrhoeae. Semchenko EA; Tan A; Borrow R; Seib KL Clin Infect Dis; 2019 Sep; 69(7):1101-1111. PubMed ID: 30551148 [TBL] [Abstract][Full Text] [Related]
11. VA-MENGOC-BC Vaccination Induces Serum and Mucosal Anti Neisseria gonorrhoeae Immune Responses and Reduces the Incidence of Gonorrhea. Reyes Díaz LM; Lastre González MSJB; Cuello M; Sierra-González VG; Ramos Pupo R; Lantero MI; Harandi AM; Black S; Pérez O Pediatr Infect Dis J; 2021 Apr; 40(4):375-381. PubMed ID: 33591079 [TBL] [Abstract][Full Text] [Related]
12. Multicentre double-blind randomised placebo-controlled trial evaluating the efficacy of the meningococcal B vaccine, 4CMenB (Bexsero), against Seib KL; Donovan B; Thng C; Lewis DA; McNulty A; Fairley CK; Yeung B; Jin F; Fraser D; Bavinton BR; Law M; Chen MY; Chow EPF; Whiley DM; Mackie B; Jennings MP; Jennison AV; Lahra MM; Grulich AE BMJ Open; 2024 Apr; 14(4):e081675. PubMed ID: 38626958 [TBL] [Abstract][Full Text] [Related]
13. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218 [No Abstract] [Full Text] [Related]
14. Human B Cell Responses to Dominant and Subdominant Antigens Induced by a Meningococcal Outer Membrane Vesicle Vaccine in a Phase I Trial. Rollier CS; Dold C; Marsay L; Linder A; Green CA; Sadarangani M; Norheim G; Derrick JP; Feavers IM; Maiden MCJ; Pollard AJ mSphere; 2022 Feb; 7(1):e0067421. PubMed ID: 35080470 [TBL] [Abstract][Full Text] [Related]
15. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study. Perrett KP; McVernon J; Richmond PC; Marshall H; Nissen M; August A; Percell S; Toneatto D; Nolan T Vaccine; 2015 Sep; 33(39):5217-24. PubMed ID: 26232542 [TBL] [Abstract][Full Text] [Related]
16. Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding. Costa I; Pajon R; Granoff DM mBio; 2014 Aug; 5(5):e01625-14. PubMed ID: 25161192 [TBL] [Abstract][Full Text] [Related]
17. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Frosi G; Biolchi A; Lo Sapio M; Rigat F; Gilchrist S; Lucidarme J; Findlow J; Borrow R; Pizza M; Giuliani MM; Medini D Vaccine; 2013 Oct; 31(43):4968-74. PubMed ID: 23954380 [TBL] [Abstract][Full Text] [Related]
19. Potential benefits of using a multicomponent vaccine for prevention of serogroup B meningococcal disease. Watson PS; Novy PL; Friedland LR Int J Infect Dis; 2019 Aug; 85():22-27. PubMed ID: 31102824 [TBL] [Abstract][Full Text] [Related]